Timothy Lansing

Tim has twenty years of drug discovery and cell-based assay development experience in the pharmaceutical industry at GlaxoSmithKline and is an expert in ELISA, EIA, ECL, and luciferase assay platforms.  As a member of the oncology biology group at GlaxoSmithKline, he used cellular and molecular approaches to identify and validate new oncology targets and to develop reagents and assays to screen small molecule inhibitors of those targets.  Tim was the biology project leader for a lead-to-candidate oncology project.  In metabolic disease research at GSK, he evaluated and validated bioassays for metabolic biomarkers, was responsible for handling and managing human clinical samples, and provided critical data for human clinical and experimental medicine studies and animal preclinical studies.

At BioAgilytix Labs, Tim has been the project manager for the bioanalysis of clinical samples for more than 10 Phase I/II clinical trials of metabolic assets and for cell-based assays for lot comparison and product release under GMP.  He has also performed immunogenicity studies under GLP.  Tim has co-authored 19 peer-reviewed publications and has presented at professional scientific meetings.  He has a B.S. in biology from the University of Georgia and an M.S. degree in zoology from the University of Iowa.